Alkem Laboratories stock slips as guarantee adds risk

Published on 09/23/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alkem Laboratories stock closed at INR 5,331.50 on September 22, 2026, down 0.61 percent on NSE. June revenue rose 2.35 percent quarter on quarter.

Alkem, INE540L01014, Illustration mit AI erstellt.

Alkem Laboratories stock (ISIN INE540L01014) closed at INR 5,331.50 on the NSE on September 22, 2026, down 0.61 percent from the previous close of INR 5,364.00. The immediate corporate development is a EUR 54.45 million guarantee linked to a EUR 49.5 million loan for subsidiary Occlutech.

Guarantee creates a measurable risk

According to Medical Dialogues on September 22, 2026, Alkem Laboratories issued the corporate guarantee to HSBC UK Bank for Occlutech Holding AG. The guarantee exceeds the underlying term loan by EUR 4.95 million, making the disclosure a concrete contingent-liability point rather than a routine operating update.

The guarantee does not by itself establish a cash outflow or a change in earnings guidance. Its significance is the relationship between the two disclosed amounts: EUR 54.45 million of guarantee exposure versus EUR 49.5 million of borrowing.

June profit grew faster than revenue

Alkem reported revenue of INR 3,892.90 crore for the quarter ended June 2026, compared with INR 3,803.39 crore in March 2026, an increase of 2.35 percent quarter on quarter, according to Upstox.

Operating profit reached INR 771.99 crore in June 2026, up 82.57 percent from INR 422.85 crore in March 2026. Reported profit rose to INR 521.49 crore from INR 251.68 crore, a 107.20 percent quarter-on-quarter increase, while earnings per share stood at INR 192.51 for June 2026. The comparison shows that profit growth materially outpaced sales growth in the latest period.

Stock remains below yearly high

The NSE quote was INR 602.00 below Alkem's 52-week high of INR 5,933.50 and INR 280.50 above its 52-week low of INR 5,051.00, based on the September 22, 2026 market snapshot. The market capitalization was INR 63,967.28 crore on the same date.

Alkem's FY26 revenue was INR 15,295.62 crore, compared with INR 13,458.26 crore in FY25, while FY26 net profit reached INR 2,353.13 crore versus INR 2,216.00 crore in FY25. These full-year figures add a longer comparison to the June quarter, with revenue growth of 13.65 percent and net-profit growth of 6.19 percent reported for fiscal year 2026.

Price holds above INR 5,300

Alkem Laboratories stock stood at INR 5,331.50 on the NSE as of September 22, 2026, with a daily change of minus 0.61 percent. The latest price, the 52-week range and the guarantee disclosure place operating progress beside a clearly defined contingent-liability risk.